GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (BUE:GILD) » Definitions » Cyclically Adjusted PS Ratio

Gilead Sciences (BUE:GILD) Cyclically Adjusted PS Ratio : 2.89 (As of May. 16, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Gilead Sciences Cyclically Adjusted PS Ratio?

As of today (2024-05-16), Gilead Sciences's current share price is ARS18359.00. Gilead Sciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was ARS6,344.51. Gilead Sciences's Cyclically Adjusted PS Ratio for today is 2.89.

The historical rank and industry rank for Gilead Sciences's Cyclically Adjusted PS Ratio or its related term are showing as below:

BUE:GILD' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 2.75   Med: 5.54   Max: 24.58
Current: 2.84

During the past years, Gilead Sciences's highest Cyclically Adjusted PS Ratio was 24.58. The lowest was 2.75. And the median was 5.54.

BUE:GILD's Cyclically Adjusted PS Ratio is ranked worse than
60.11% of 747 companies
in the Drug Manufacturers industry
Industry Median: 2.17 vs BUE:GILD: 2.84

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Gilead Sciences's adjusted revenue per share data for the three months ended in Mar. 2024 was ARS4,517.205. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is ARS6,344.51 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Gilead Sciences Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Gilead Sciences's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences Cyclically Adjusted PS Ratio Chart

Gilead Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.48 3.62 3.86 4.01 3.46

Gilead Sciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.76 3.41 3.24 3.46 3.11

Competitive Comparison of Gilead Sciences's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - General subindustry, Gilead Sciences's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gilead Sciences's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Gilead Sciences's Cyclically Adjusted PS Ratio falls into.



Gilead Sciences Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Gilead Sciences's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=18359.00/6344.51
=2.89

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gilead Sciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Gilead Sciences's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=4517.205/131.7762*131.7762
=4,517.205

Current CPI (Mar. 2024) = 131.7762.

Gilead Sciences Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 31.909 100.560 41.815
201409 31.074 100.428 40.774
201412 39.040 99.070 51.929
201503 42.688 99.621 56.467
201506 48.642 100.684 63.663
201509 51.891 100.392 68.113
201512 74.893 99.792 98.896
201603 80.612 100.470 105.730
201606 80.226 101.688 103.964
201609 83.552 101.861 108.090
201612 87.578 101.863 113.297
201703 75.975 102.862 97.331
201706 89.401 103.349 113.992
201709 86.515 104.136 109.479
201712 86.123 104.011 109.113
201803 77.665 105.290 97.202
201806 107.692 106.317 133.481
201809 157.557 106.507 194.939
201812 168.987 105.998 210.084
201903 160.900 107.251 197.694
201906 198.904 108.070 242.537
201909 247.363 108.329 300.902
201912 275.831 108.420 335.251
202003 271.150 108.902 328.105
202006 280.550 108.767 339.898
202009 387.214 109.815 464.651
202012 471.445 109.897 565.305
202103 458.466 111.754 540.604
202106 467.410 114.631 537.318
202109 574.980 115.734 654.678
202112 579.692 117.630 649.409
202203 560.683 121.301 609.102
202206 597.830 125.017 630.153
202209 775.960 125.227 816.545
202212 979.262 125.222 1,030.519
202303 995.113 127.348 1,029.717
202306 1,258.951 128.729 1,288.755
202309 1,962.727 129.860 1,991.696
202312 2,046.338 129.419 2,083.603
202403 4,517.205 131.776 4,517.205

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Gilead Sciences  (BUE:GILD) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Gilead Sciences Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Gilead Sciences's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Gilead Sciences (BUE:GILD) Business Description

Address
333 Lakeside Drive, Foster, CA, USA, 94404
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.